Based on input from an international panel of experts, this book provides first-hand experience of the challenges and opportunities facing the delivery of regenerative medicines to patients. It highlights key issues beyond science and clinical translation, such as finance and business models, intellectual property and regulatory landscapes as well as questions of how regenerative medicines will be evaluated for reimbursement. This book will become a pivotal reference to anyone within the healthcare sector interested in understanding and investing in the delivery of regenerative medicines to the benefit of patients.
Introduction What Is Regenerative Medicine? J. Polak Finance A New Political-Financial Paradigm, R. Klein and A. Trounson Investment Models 4. Public Funding in Australia, G. Macdonald Capitalising On A 50-Year Legacy, A. Lyall Investing in Regenerative Medicine: What Drives the Private Investor? C. Prescott Public Investment Models: Coming Out of the Closet And Going Public! R. Benjamin Business Models Cell-Based Products: Allogenic, P. Kemp Autologous Cell Based Products: Fulfilling the Promise of Cell Therapy, E. Bravo and M. Blanco-Molina Business Models for Cord Blood, S. Watt Changing the Game of Drug Discovery, J. Walker Discovery of Small Molecule Regenerative Drugs, Y. Choo The Adoption of Therapeutic Stem Cell Technologies by Large Pharmaceutical Companies, A. Vertes Role of Tools and Technologies Companies in the Successful Commercialization of Regenerative Medicine, J. Goswami Key Considerations in Manufacturing of Cellular Therapies, R. Preti State of the Global Regenerative Medicine Industry, L. Buckler, R. Margolin, and S. Haecker Intellectual Property Regenerating Ip: Europe After Warf, J. Hitchcock and D. Crease Protecting Regenerative Medicine Intellectual Propery in the Use: Problems and Strategies, D. Resnick, R. Eisenstein, and J. McWilliams Impact of Indian Policies and Laws on Regenerative Medicine Patent Applications, P. Ganguli The Regulatory Landscape A CATalyst for Change: Regulating Regenerative Medicines in Europe, C. Bravery The US Regulatory Reimbursement, Political Environment and Strategies for Reform, M. Werner Reimbursement The Fourth Hurdle: Reimbursement Strategies for Regenerative Medicine, F. Meurgey and Micheline Cellular Therapies and Regenerative Medicine: Preparing for Reimbursement in the United States, E. Faulkner The Adoption and Evaluation of Regenerative Medicine and the NHS, M. Parton Insurance If You Build It Will They Insure It? M. Clark